Leerink Partners Issues Pessimistic Forecast for Ardent Health (NYSE:ARDT) Stock Price

Ardent Health (NYSE:ARDT) had its target price dropped by equities researchers at Leerink Partners from $16.00 to $15.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners’ target price would suggest a potential upside of 68.35% from the company’s current price.

ARDT has been the subject of a number of other research reports. KeyCorp downgraded Ardent Health from an “overweight” rating to a “sector weight” rating in a research report on Monday, November 17th. Wall Street Zen lowered Ardent Health from a “buy” rating to a “hold” rating in a research report on Sunday, November 23rd. Morgan Stanley reissued an “equal weight” rating and set a $12.00 price objective (down from $22.00) on shares of Ardent Health in a report on Friday, November 14th. JPMorgan Chase & Co. cut their target price on shares of Ardent Health from $12.00 to $11.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Finally, Stephens lowered their price target on shares of Ardent Health from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Friday, November 14th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Ardent Health has a consensus rating of “Hold” and an average target price of $14.50.

Ardent Health Price Performance

Shares of ARDT stock opened at $8.91 on Friday. Ardent Health has a 1 year low of $8.07 and a 1 year high of $15.48. The company has a current ratio of 2.08, a quick ratio of 1.95 and a debt-to-equity ratio of 0.67. The firm’s 50 day moving average is $9.00 and its 200-day moving average is $10.99. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of 9.28, a PEG ratio of 6.19 and a beta of 0.46.

Ardent Health (NYSE:ARDT) last issued its quarterly earnings results on Wednesday, March 4th. The company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). Ardent Health had a net margin of 2.15% and a return on equity of 14.46%. The company had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.63 billion. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. Sell-side analysts forecast that Ardent Health will post 1.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Ardent Health

Hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd grew its position in shares of Ardent Health by 1,177.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,862 shares of the company’s stock worth $25,000 after buying an additional 2,638 shares during the period. CWM LLC raised its position in shares of Ardent Health by 990.6% in the 2nd quarter. CWM LLC now owns 2,203 shares of the company’s stock valued at $30,000 after acquiring an additional 2,001 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Ardent Health during the 3rd quarter worth approximately $61,000. Monetary Solutions Ltd acquired a new position in Ardent Health during the fourth quarter valued at approximately $79,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Ardent Health during the third quarter valued at approximately $80,000.

Key Ardent Health News

Here are the key news stories impacting Ardent Health this week:

• Positive Sentiment: Company reiterated cost‑savings plan and set a $485M–$535M 2026 EBITDA target tied to its “impact” program and expanded AI‑driven care initiatives — a potential multi‑year margin recovery catalyst if realized. Ardent Health outlines $485M-$535M 2026 EBITDA target
• Neutral Sentiment: Leerink Partners trimmed its price target to $15 from $16 but maintained an “outperform” rating, signaling some analyst conviction about upside despite near‑term headwinds. Leerink lowers Ardent Health price target
• Negative Sentiment: Q4 results missed expectations: $0.32 EPS vs. $0.35 consensus and revenue below estimates; management issued FY‑2026 EPS guidance (0.90–1.27) below consensus (~1.40) and trimmed revenue outlook — a clear near‑term earnings downgrade that pressures valuation and investor confidence. Ardent Q4 results and guidance update
• Negative Sentiment: Allegations over receivables accounting (an alleged $97M “accounting shock” and use of a rigid 180‑day reserve “cliff”) have drawn a Hagens Berman probe — increasing regulatory, restatement or reserve‑adjustment risk. Hagens Berman investigating Ardent Health accounting
• Negative Sentiment: Multiple shareholder‑rights firms have filed or are soliciting lead‑plaintiff claims (March 9 lead plaintiff deadline), amplifying litigation risk and potential future liabilities or settlements that can weigh on the stock. Gross Law Firm securities class action notice

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.